Embera NeuroTherapeutics, Inc., is a specialty biopharmaceutical company focused on developing treatments for cocaine use disorder, tobacco use disorder, and other addictions, for which there are a limited range of effective drug therapies or no approved treatment options. Embera is developing a novel, patented drug combination (EMB-001) targeting specific brain functions related to stress response that drive craving and relapse associated with these disorders, an approach based on years of NIH-funded research on the role of stress in addiction and potential treatments. EMB-001 has been tested with promising clinical results in a Phase 1 safety and pharmacokinetic study and in a published pilot study in cocaine-dependent human subjects.
In addition, potential efficacy for cocaine, nicotine and methamphetamine use disorders has been shown in published preclinical models of these addictions. Embera's preclinical study in nicotine addiction for EMB-001 demonstrated a statistically significant reduction in nicotine self-administration— up to an 80% reduction, versus only a 50% reduction with varenicline (Chantix®).
Embera has completed a Phase 1 safety and pharmacokinetic study in smokers, meeting the primary endpoints of the study. This work enables further clinical development of EMB-001 in the cocaine use disorder and tobacco use disorder indications. EMB-001 development has been supported by a combination of venture and private investment as well as NIH grant funding from the National Institute on Drug Abuse (NIDA).